Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Vitae Pharmaceuticals (NASDAQ: VTAE) acted responsibly on behalf of investors’ profitability in the planned $639 million sale to Allergan plc.

On September 14, 2016, Vitae Pharmaceuticals (NASDAQ: VTAE) and Allergan plc announced that they had entered into a merger agreement. Under the terms of the merger agreement, Allergan will offer Vitae shareholders $21.00 per share in cash for all outstanding shares.    

Based in Fort Washington, Pennsylvania, and founded in 2001 Vitae Pharmaceuticals focuses on discovering and developing novel and small molecule drugs for diseases with unmet medical needs.

The investigation focuses on whether NASDAQ: VTAE investors received the highest price and whether the directors of Vitae Pharmaceuticals acted in the best interest of Vitae Pharmaceuticals company and its shareholders.   

If you purchased Vitae Pharmaceuticals (NASDAQ: VTAE) prior to September 14, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185